Increase in Raynaud’s Disease Grows Therapeutic Market

Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/ on line 21
  • The growing prevalence of autoimmune disease is contributing to the overall growth of this market.
  • There are no current FDA approved treatment options for Raynaud’s Disease.
  • North America accounted for major market share.

As per Cleveland Clinic, primary Raynaud’s phenomenon affects around 5% to 10% of the general population. This phenomenon is predominantly observed among the female population aged 15 to 30 years. Secondary Raynaud’s phenomenon is comparatively more prevalent as its occurrence is associated with the presence of autoimmune diseases. Raynaud’s disease occurs in 90% to 95% of scleroderma patients, 85% of mixed connective tissue disease patients, 40% of systemic lupus erythematous patients and 40% of antisynthetase syndrome patients. The growing prevalence of autoimmune disease thus increases the occurrence of Raynaud’s syndrome, contributing to the overall growth of this market.

For more info

According to the National Institute of Health (NIH), 23.5 million Americans have reported to have at least one autoimmune disease. The NIH also reported that the direct healthcare costs associated with autoimmune diseases account to around $100 million. According at a review article published by McFarlane IM et al. (McFarlane IM, Bhamra MS, Kreps A, Iqbal S, Al-Ani F, et al. (2018) Gastrointestinal Manifestations of Systemic Sclerosis. Rheumatology (Sunnyvale) 8: 235. doi:10.4172/2161-1149.1000235), the prevalence of scleroderma among the U.S. population accounts to 276 persons per million and incidence rates account to 20 new cases per million each year. The growing prevalence of scleroderma thus contributes to the overall growth of the Raynaud’s disease therapeutic market.

So far, there are no FDA approved treatment options for Raynaud’s disease. Calcium channel blockers, vasodilators and alpha-blockers are prescribed to relieve symptoms. The requirement of a target based therapy remains a major unmet need of this market, thus creating market opportunities for existing and emerging industrial players. The pipeline molecules BAY63-2521 (Riociguat) by Bayer AG and RayVa (Alprostadil) by Apricus Biosciences, Inc., are being developed for Raynaud’s disease treatment, ensuring potential market growth during the forecast period from 2018 to 2026.

Download Sample research report with TOC and Figures

Raynaud’s disease therapeutics market comprises a vast market outreach across the globe. North America accounted for major market share owing to the growing prevalence of autoimmune conditions leading to Raynaud’s disease, rising research activities and increase healthcare expenditure. Asia Pacific is also a potential market owing to its developing healthcare infrastructure, rising awareness on healthcare and growing Raynaud’s disease prevalence.

The Global Raynaud’s Disease Therapeutic Market is segmented as follows:

  • By Drug Class
    • Calcium channel blockers
      • Nifedipine
      • Amlodipine
      • Felodipine
    • Alpha blockers
      • Prazosin
      • Doxazosin
    • Vasodilators
      • Losartan
      • Fluoxetine
    • Pipeline molecules
      • BAY63-2521 (Riociguat)
      • RayVa (Alprostadil)
  • By Geography
    • North America
      • United States
      • Canada
    • Europe
      • United Kingdom
      • Germany
      • Rest of Europe
    • Asia Pacific
      • Japan
      • China
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC
      • Rest of Middle East & Africa

The global Raynaud’s disease therapeutic market comprises industrial leaders namely, Apricus Biosciences, Inc., Bayer AG, Allergan plc., Covis Pharmaceuticals, Inc., GlaxoSmithKline plc., Zydus Pharma USA,Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd. and others.

Do inquiry before purchase the Industry Research Report

This report offers:

  • A through study of global Raynaud’s disease therapeutics market
  • Market analysis for the period from 2016 to 2026, with 2016 as the historical year and 2017 to be the base year
  • CAGR for the period from 2018 to 2026 with respect to the entire market and each segment considered have been incorporated in this report
  • A qualitative analysis on the pipeline molecule
  • Qualitative information of the market dynamic factors such as market drivers, challenges and opportunities
  • An elaborative study on the competitive landscape and profiling of the key industrial leaders

Charlie Gefen

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Leave a Reply